Biote Corp
BTMD
View Detailed Chart
2.230USD
+0.110+5.19%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
68.42MMarket Cap
2.46P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+5.19%
5 Days
+6.70%
1 Month
-12.20%
6 Months
-42.23%
Year to Date
-14.23%
1 Year
-53.64%
View Detailed Chart
TradingKey Stock Score of Biote Corp
Currency: USD Updated: 2026-02-06Key Insights
Biote Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 83 out of 156 in the Professional & Commercial Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.84.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Biote Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Biote Corp Highlights
StrengthsRisks
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.54% year-on-year.
Undervalued
The company’s latest PE is 2.46, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 20.37M shares, decreasing 0.13% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 2.54K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.51.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
4.843
Target Price
+128.46%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Biote Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Biote Corp Info
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
Ticker SymbolBTMD
CompanyBiote Corp
CEOChristensen (Bret)
Websitehttps://haymakeracquisition.com/
Related Instruments
-2.75%
+0.08%
-1.14%
+0.91%
+6.38%
+0.56%
+6.06%
+3.62%
+7.16%
+0.03%
-1.53%
-0.27%
+1.30%
+0.37%
0.00%
+6.48%
+4.83%
+2.67%
+0.56%
+5.73%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
69086.400
-883.730 (-1.26%)
282.580
+22.390 (+8.61%)
2050.500
-1.230 (-0.06%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
